Liucheng Li

1.5k total citations
49 papers, 1.2k citations indexed

About

Liucheng Li is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Liucheng Li has authored 49 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 6 papers in Surgery and 6 papers in Oncology. Recurrent topics in Liucheng Li's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (14 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers) and Laser Design and Applications (4 papers). Liucheng Li is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (14 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers) and Laser Design and Applications (4 papers). Liucheng Li collaborates with scholars based in China, United States and Czechia. Liucheng Li's co-authors include Jian Gao, Jun Li, Lian‐Di Kan, Liang Xu, Wencheng Zhou, Wenhui Cui, Xiaoting Mo, Zhihui Zhang, Delin Li and Ping Zhao and has published in prestigious journals such as Scientific Reports, The FASEB Journal and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Liucheng Li

40 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liucheng Li China 18 429 405 230 103 102 49 1.2k
Wupeng Liao Singapore 20 223 0.5× 461 1.1× 199 0.9× 117 1.1× 68 0.7× 39 1.2k
Fan He China 21 187 0.4× 541 1.3× 397 1.7× 128 1.2× 125 1.2× 63 1.7k
Narayanan Venkatesan Canada 21 392 0.9× 566 1.4× 104 0.5× 69 0.7× 162 1.6× 44 1.6k
Chaoyang Tong China 19 190 0.4× 262 0.6× 234 1.0× 220 2.1× 87 0.9× 58 972
Hongyi Tan China 16 279 0.7× 460 1.1× 459 2.0× 155 1.5× 110 1.1× 51 1.2k
Juan Wei China 22 312 0.7× 824 2.0× 242 1.1× 192 1.9× 90 0.9× 68 1.6k
Yuan Chen China 21 251 0.6× 395 1.0× 105 0.5× 76 0.7× 131 1.3× 66 1.1k
Xianzhang Huang China 19 117 0.3× 366 0.9× 159 0.7× 152 1.5× 79 0.8× 95 1.1k

Countries citing papers authored by Liucheng Li

Since Specialization
Citations

This map shows the geographic impact of Liucheng Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liucheng Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liucheng Li more than expected).

Fields of papers citing papers by Liucheng Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liucheng Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liucheng Li. The network helps show where Liucheng Li may publish in the future.

Co-authorship network of co-authors of Liucheng Li

This figure shows the co-authorship network connecting the top 25 collaborators of Liucheng Li. A scholar is included among the top collaborators of Liucheng Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liucheng Li. Liucheng Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Bo, Liying Chen, Yan Hu, et al.. (2025). A retrospective analysis of small molecule targeting inhibitor usage for lung cancer among outpatients in six major regions of China (2016–2022). Frontiers in Pharmacology. 16. 1700389–1700389.
2.
Xu, Feng, et al.. (2025). Antithrombotic management in an elderly CABG patient with nephrotic syndrome: a case report. Frontiers in Cardiovascular Medicine. 12. 1595027–1595027.
3.
Xu, Feng, et al.. (2025). Bleeding in Antiplatelet Therapy: A Narrative Review of Clinical Evidence and the Roles of Pharmacists and Nurses. Reviews in Cardiovascular Medicine. 26(11). 45077–45077.
4.
Li, Liucheng, Xiaoye Hu, Xiaotong Sun, et al.. (2025). Quinoa alleviates the diabetic symptoms of db/db mice by upregulating insulin signaling and modulating gut microbiota composition. Journal of Functional Foods. 128. 106813–106813. 2 indexed citations
5.
Jin, Lei, Guoquan Chen, Jun Xie, et al.. (2025). Real-World Safety of Anti-EGFR Antibodies: 20-Year Pharmacovigilance of Cetuximab and Panitumumab. International Journal of Medical Sciences. 22(15). 4131–4144. 1 indexed citations
6.
Wang, Chen, Bo Chen, Qin Chen, Jie Chen, & Liucheng Li. (2025). Trends in Combinatorial Endocrine Therapy for Breast Cancer Across Six Cities in China(2016-2021). Risk Management and Healthcare Policy. Volume 18. 1503–1511. 1 indexed citations
7.
Li, Liucheng, et al.. (2025). Unraveling the role of FGF7 in osteoarthritis and osteoporosis: Therapeutic implications and challenges. The FASEB Journal. 39(6). e70479–e70479.
8.
Li, Liucheng, Zhihui Zhang, Miaomiao Chen, Feng Xu, & Kaili Mao. (2025). Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of the FDA Adverse Event Reporting System and Japanese Adverse Drug Event Report databases, and the role of pharmacists. International Journal of Surgery. 112(2). 3612–3624.
9.
Li, Fuming, Pingyu Liu, Mi Wen, et al.. (2024). Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer. Nature Cancer. 5(1). 131–146. 37 indexed citations
10.
Wen, Mi, J. Q. You, Liucheng Li, et al.. (2024). BET inhibition induces GDH1-dependent glutamine metabolic remodeling and vulnerability in liver cancer. PubMed. 3(4). loae016–loae016. 2 indexed citations
11.
Ma, Mingming, et al.. (2024). Statin-Associated Liver Dysfunction and Muscle Injury: epidemiology, Mechanisms, and Management Strategies. International Journal of General Medicine. Volume 17. 2055–2063. 8 indexed citations
12.
Li, Liucheng, et al.. (2024). Escitalopram-induced sinus bradycardia in coronary heart disease combined with depression: a case report and review of literature. Frontiers in Cardiovascular Medicine. 10. 1133662–1133662. 7 indexed citations
13.
Zhu, Xiaobin, et al.. (2023). Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence. Drug Development Research. 85(1). e22131–e22131. 2 indexed citations
14.
Guan, Yan, Liucheng Li, Lian‐Di Kan, & Qiang-min Xie. (2022). Inhalation of Salvianolic Acid B Prevents Fine Particulate Matter‐Induced Acute Airway Inflammation and Oxidative Stress by Downregulating the LTR4/MyD88/NLRP3 Pathway. Oxidative Medicine and Cellular Longevity. 2022(1). 5044356–5044356. 18 indexed citations
15.
Zhu, Xiaobin, Zhihui Zhang, Lihua Sun, et al.. (2021). Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review. Integrative Medicine Research. 10(4). 100778–100778. 8 indexed citations
16.
Li, Liucheng. (2015). Establishment of fingerprint of total glucosides of Yupingfeng by HPLC. Chinese Journal of Hospital Pharmacy. 1 indexed citations
17.
18.
Li, Liucheng, Delin Li, Liang Xu, et al.. (2015). High-Mobility Group Box 1 Mediates Epithelial-to-Mesenchymal Transition in Pulmonary Fibrosis Involving Transforming Growth Factor-β1/Smad2/3 Signaling. Journal of Pharmacology and Experimental Therapeutics. 354(3). 302–309. 59 indexed citations
19.
Mo, Xiaoting, Wencheng Zhou, Wenhui Cui, et al.. (2015). Inositol-requiring protein 1 – X-box-binding protein 1 pathway promotes epithelial–mesenchymal transition via mediating snail expression in pulmonary fibrosis. The International Journal of Biochemistry & Cell Biology. 65. 230–238. 26 indexed citations
20.
Li, Liucheng, Jun Li, & Jian Gao. (2014). Functions of Galectin-3 and Its Role in Fibrotic Diseases. Journal of Pharmacology and Experimental Therapeutics. 351(2). 336–343. 209 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wupeng Liao Breakdown of academic impact, for papers by Fan He Breakdown of academic impact, for papers by Narayanan Venkatesan Breakdown of academic impact, for papers by Chaoyang Tong Breakdown of academic impact, for papers by Hongyi Tan Breakdown of academic impact, for papers by Juan Wei Breakdown of academic impact, for papers by Yuan Chen Breakdown of academic impact, for papers by Xianzhang Huang
Rankless by CCL
2026